Casdatifan data were better on every efficacy measure evaluated, across all four monotherapy cohorts (n=121) of the Phase 1/1b ARC-20 study in late-line metastatic kidney cancer, relative to published ...
Scientists use cell death, whether by apoptosis or necrosis, to evaluate the toxicity or effectiveness of substances of interest, including potential therapeutic agents. For example, researchers will ...
BOSTON--(BUSINESS WIRE)--DeepCure, a therapeutics company using AI to discover novel therapies for inflammation and immune diseases, announced today the discovery of potent, selective oral small ...
Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa ...
WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic Ensemble® platform to advance innovative small ...
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton’s tyrosine kinase (BTK) inhibitor treatment, and new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback